Valuation: Botanix Pharmaceuticals Limited

Market Cap 30.1M 21.19M 19.01M 17.58M 15.92M 29.74M 2.02B 210M 83.71M 1.06B 79.52M 77.85M 3.35B P/E 2027 *
-0.04x
P/E 2028 * -0.22x
Enterprise Value 35.1M 24.71M 22.17M 20.5M 18.56M 34.68M 2.35B 245M 97.62M 1.23B 92.73M 90.78M 3.91B EV / Sales 2027 *
0.63x
EV / Sales 2028 * 0.21x
Free-Float
89.38%
Yield 2027 *
-
Yield 2028 * -
1 week-8.33%
Current month-38.89%
1 month-38.89%
3 months-47.62%
6 months-65.62%
Current year-91.85%
1 week 0.01
Extreme 0.01
0.01
1 month 0.01
Extreme 0.01
0.02
Current year 0.01
Extreme 0.01
0.15
1 year 0.01
Extreme 0.01
0.15
3 years 0.01
Extreme 0.01
0.54
5 years 0.01
Extreme 0.01
0.54
10 years 0.01
Extreme 0.01
0.54
Manager TitleAgeSince
Chief Executive Officer - 24/08/2023
Director of Finance/CFO - 26/03/2024
President 67 20/05/2019
Director TitleAgeSince
Director/Board Member - 01/07/2016
Chairman 67 18/07/2019
Director/Board Member - 18/10/2026
Date Insider Type Main position Quantity % Market Cap. Importance
24/04/26 Free

Director

1,666,667 0.0751%
24/04/26 Free

Chairman

1,666,667 0.0751%
24/04/26 Free

Director

1,666,667 0.0751%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-8.33%-92.14%-92.14% 21.17M
+0.52%+1.43%+57.17%+127.85% 1,143B
+0.96%+5.15%+45.00%+84.35% 647B
+0.10%+0.73%+26.07%+102.18% 506B
-0.05%+1.73%+52.74%+65.27% 384B
-1.14%-6.40%+61.20%+36.63% 350B
+0.34%+1.84%+30.70%+52.69% 293B
-0.45%+1.19%+2.89%+24.92% 265B
+0.30%+2.76%+54.21%+71.14% 242B
-0.39%+3.50%+34.84%+104.38% 197B
Average +0.03%-0.07%+27.27%+57.73% 402.76B
Weighted average by Cap. +0.22%+0.71%+44.47%+86.94%

Financials

2027 *2028 *
Net sales 56.07M 39.47M 35.41M 32.74M 29.65M 55.4M 3.76B 391M 156M 1.97B 148M 145M 6.24B 105M 73.59M 66.02M 61.04M 55.28M 103M 7.01B 730M 291M 3.67B 276M 270M 11.64B
Net income -39.23M -27.62M -24.78M -22.91M -20.75M -38.76M -2.63B -274M -109M -1.38B -104M -101M -4.37B -2.93M -2.06M -1.85M -1.71M -1.55M -2.9M -197M -20.48M -8.16M -103M -7.75M -7.59M -327M
Net Debt 5M 3.52M 3.16M 2.92M 2.64M 4.94M 335M 34.91M 13.9M 175M 13.21M 12.93M 557M -7.9M -5.56M -4.99M -4.61M -4.18M -7.81M -530M -55.16M -21.97M -277M -20.87M -20.43M -880M
Projected Income Statement - Annual - Botanix Pharmaceuticals Limited
Logo Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is an Australia-based dermatology company. The Company’s lead product is Sofdra (sofpironium) topical gel, 12.45%, a prescription anticholinergic medicine used on the skin (topical), to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children nine years of age and older. Sofdra regulates sweating at the site of application, by binding to the primary sweat receptor and thereby blocking the sweat signal. Its product pipeline targets the various skin diseases, such as BTX 1503 for Acne, BTX 1702 for Rosacea, BTX 1204A for Atopic Dermatitis, and BTX 1801 for Hemodialysis Patients. Its BTX 1503 is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. BTX 1702 is used for the treatment of papulopustular rosacea. BTX 1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA).
Employees
11
Date Price Change Volume
28/10/26 A$0.0110 0.00% 21,228,655
27/10/26 A$0.0110 -15.38% 26,467,462
26/10/26 A$0.0130 +8.33% 7,598,231
23/10/26 A$0.0120 -7.69% 607,115
22/10/26 A$0.0130 0.00% 3,056,593
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Botanix Pharmaceuticals Limited
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
0.0110AUD
Average target price
0.4400AUD
Spread / Average Target
+3,900.00%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Botanix Pharmaceuticals Limited